IsoRay (ISR +0.52%) announces highlights from its presentation at the 21st Annual Meeting of the Society for Neuro-Oncology
Global Blood Therapeutics (GBT +3.22%) announces that the European Commission has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease
Sangamo Biosci (SGMO +3.85%) announces that its collaborative zinc finger nuclease-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ
Decliners on news:
Arrowhead (ARWR -62.76%) will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT
Cerecor (CERC -52.54%) announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint
Ocular Therapeutix (OCUL -3.97%) enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln
Gainers on earnings:
Champions Oncology (CSBR +17.8%) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis
RA Pharma (RARX +0.52%) reports Q3 results; on track to initiate Phase 2 Clinical Trial of RA101495 in 1Q 2017
Upgrades/Downgrades:
Xtant Medical (XTNT +15.5%) initiated with a Buy at Aegis Capital; tgt $3.50
Arbutus Biopharma (ABUS +12.26%) Chardan Capital Markets Upgraded to BUY (from Neutral) — Price Target: 4
UnitedHealth (UNH +1.22%) target raised to $175 at RBC Capital Mkts
Abaxis (ABAX -2.53%) downgraded to Neutral from Buy at Northcoast
Рынок приобретает черты предновогоднего, что чревато потерей ликвидности и объемов.Меньше торгуем, уменьшаем объем, стопы ставим глубже! Но и здесь могут быть всплески.В целом рынок очень тонкий, будьте осторожней!
Buckle (BKE -1.5% the following trading day) reported October comps of -15.5%% vs -5.8% year ago and -15.5% prior month and prelim Q3 sales of $239.2 mln vs $249 mln CapIQ estimate (does not provide EPS guidance).
Cato (CATO 0.2%) reported Oct comps of -6%% vs +1% year ago and -9.0% last month. Co issued upside Q3 EPS guidance of $0.24-0.28 vs $0.13-0.18 prior guidance and $0.09 single analyst estimate but prelim Q3 sales were slightly below single estimate.
Costco (COST -1.2%) reported comps of +2% (core +2%)% vs -1% (core +5%) year ago and 1% (core +1%) prior month.
Fred's (FRED -9.2%) reported comps of -3.4%% vs +2.3% year ago and -4.9% prior month. Co also prelim Q3 sales of $516.7 mln vs $519.2 mln Cap IQ consensus; suspends previously issued guidance for the 2H16 .
L Brands (LB -0.9%) reported comps of +1% (VS -2%, BBW +6%)% vs +5% (VS +7%, BBW +5%) year ago and 3% (VS 0%, BBW +9%) prior month. Co also issued downside guidance earlier in the week for Q3 (Oct), sees Q3 EPS of ~$0.40, prior $0.40-0.45; guides for October same store sales +1% (VS -2%, BBW +6%); November comps to be up low-single digits.
PriceSmart (PSMT +2.8%) reported comps of -0.1%% vs +3.2% year ago and +0.5% prior month.
Zumiez Inc (ZUMZ +2.2%) reported comps of +10.2%% vs -8.1% year ago and +6.3% prior month. Co also raised Q3 EPS guidance to $0.35-0.36, prior $0.29-0.30 vs. $0.30 Capital IQ Consensus Estimate based primarily on higher than planned sales.
Мартын Тимофеев, на самом деле неверно сравнивать стоимость ВТБ и Газпрома. В ВТБ было около десятка допэмиссий. Размытие гигантское. С учётом всех этих выпущенных за 17 лет бумаг капитализация не ...
«Норильский никель» готовит базу для будущего роста доходов Компания «Норильский никель» объявила об утверждении ее советом директоров бюджета на следующий год. Ключевым ее пунктом является инвестицио...
Biggest point losers: SHW 270.85(-5.47), CHTR 275.45(-5.04), COO 165.51(-4.64), NVRO 75.5(-4.56), ADSK 71.23(-4.03), DXCM64.23(-3.84), GWPH 112.6(-3.7), GWRE 54.14(-3.41), CI 135.06(-3.24), AVGO 172.44(-3.01), RARE 81.35(-2.84), ILMN 133.75(-2.79), AEO16.3(-2.62), BIIB 300.4(-2.38), RL 106.29(-2.32), RCL 80.73(-2.19), ALGN 93.36(-2.15), IBB 278.2(-2.11), TLT 120.12(-2.11), TQQQ126.21(-1.95), VLO 61.87(-1.9), JCOM 74.69(-1.85), AGN 190.79(-1.85), NEE 115.47(-1.8), NTNX 32.3(-1.79)
- IsoRay (ISR +0.52%) announces highlights from its presentation at the 21st Annual Meeting of the Society for Neuro-Oncology
- Global Blood Therapeutics (GBT +3.22%) announces that the European Commission has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease
- Sangamo Biosci (SGMO +3.85%) announces that its collaborative zinc finger nuclease-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ
Decliners on news:- Arrowhead (ARWR -62.76%) will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT
- Cerecor (CERC -52.54%) announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint
- Ocular Therapeutix (OCUL -3.97%) enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln
Gainers on earnings:- Champions Oncology (CSBR +17.8%) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis
- RA Pharma (RARX +0.52%) reports Q3 results; on track to initiate Phase 2 Clinical Trial of RA101495 in 1Q 2017
Upgrades/Downgrades: